Affiliated Treatment Facilities
Contact Information
Alaska Oncology & Hematology LLC
2925 Debarr Road, Suite 300
Anchorage, AK 99508
01. Doctor Overview
Doctor Overview
Dr. Steven Y. Liu is a medical oncologist in Anchorage, Alaska. He has a Medical Degree from Northwestern University and over 33 years of experience. His specialties include oncology (cancer), hematology (the study of blood) and internal medicine. He is currently the research director for Alaska Oncology & Hematology LLC.
Dr. Liu often treats peritoneal cancers. The second most common type of mesothelioma affects the peritoneum (lining of the abdomen).
Dr. Liu treats cancer patients using several methods. These include chemotherapy drugs like cisplatin and immunotherapy drugs like Keytruda® (pembrolizumab) and Opdivo® (nivolumab). All these drugs are common mesothelioma treatments. He also provides patients with the option to take part in clinical trials.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Cancer chemotherapy, cancer pain, cancer-related depression, cancer risk assessment, chemoradiation, lung cancer genomics, pulmonary metastases, retroperitoneal mass and side effects of cancer treatment.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, Merit Award from the American Society of Clinical Oncology (ASCO)
Education & Experience:
- Medical Degree from Northwestern University Feinberg School of Medicine
- Internship and residency at the University of California
- Residency and fellowship at the University of Washington Medical Center
03. Publications
Publications
Fixed-duration subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: updated results from the phase ii morningsun study. Blood. 2024 Nov 5;144(Supplement 1):3008–3008.
A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (Nivo) + relatlimab (Rela) fixed-dose combination (Fdc) subcutaneous (Sc) vs NIVO + RELA FDC intravenous (Iv) and NIVO SC vs NIVO IV in participants with melanoma. JCO. 2024 Jun 1;42(16_suppl):TPS9619–TPS9619.
EVOKE-01: A phase 3 study of sacituzumab govitecan (Sg) versus docetaxel in patients with non–small cell lung cancer (Nsclc) progressing on or after platinum-based chemotherapy and checkpoint inhibitors. JCO. 2022 Jun 1;40(16_suppl):TPS9149–TPS9149.
